Microfluidics Specialist Dolomite Signs Collaboration Agreement with Sphere Fluidics
News May 11, 2011
The Dolomite Centre Ltd, has signed a collaboration agreement with Sphere Fluidics, a leading company in commercializing picodroplet technology that performs thousands of simultaneous analyses on single cells and small populations of molecules.
Sphere Fluidics is commercializing new lab-on-a-chip and picodroplet technology developed at Cambridge University by company founders Professor Chris Abell and Professor Wilhelm Huck. Sphere Fluidics offers extensive expertise in miniaturized Discovery Systems and Services based on microfluidics and picodroplets.
Focussing on storing and retrieving individual picodroplets containing a unique sample, their technology benefits a wide range of applications, including rapid antibody discovery, identification of novel algal strains and the generation of new biocatalysts.
The agreement between Sphere Fluidics and Dolomite establishes core areas where the two companies will collaborate:
- Dolomite will become the exclusive worldwide distributor for Sphere Fluidics’ standard products, including a range of PDMS picodroplet handling chips and surfactants;
- Dolomite will develop and sell new products in picodroplet technology, based on Sphere Fluidics’ expertise.
“We are very excited about the agreement with Sphere Fluidics,” commented Dr. Andrew Lovatt, CEO of Dolomite. “Microdroplets are a fascinating and fast growing area of research, especially useful where tests need to be conducted on only a few nanolitres of sample containing, for example, cells or DNA. Sphere Fluidics’ scientific know-how and capability in the core areas of picodroplet based systems will enable Dolomite to enhance our market leading solutions, for example by adding further functionality such as droplet merging. This will give our customers new capabilities, and strengthen our position as world leader in microfluidic solutions through a more comprehensive product and service solution”, said Dr. Lovatt.
“Sphere Fluidics is very pleased to enter this collaboration with Dolomite. We are impressed with Dolomite’s technical, manufacturing and commercial expertise. Specifically, we see superb synergy between our scientific and their engineering skills. They also provide us with a rapid “route to market”. We are all looking forward to a very successful collaboration”, said Dr Frank F. Craig, CEO of Sphere Fluidics.
Instead of searching for a needle in a haystack, what if you were able to sweep the entire haystack to one side, leaving only the needle behind? That's the strategy researchers followed in developing a new microfluidic device that separates elusive circulating tumor cells (CTCs) from a sample of whole blood.READ MORE